EUVIMEDEUVIMED entdecken
Leserbrief

Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study

Antonio Avallone iD, Alfonso De Stefano iD, Davide Ciardiello

Journal of Clinical Oncology · 10.08.2026 · 44 (23) · 2253-2254

DOI: 10.1200/jco-26-00227 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2026. Verfasst von Antonio Avallone und 2 weiteren Autor:innen. Beteiligte Einrichtung: Antonio Avallone, MD, and Alfonso De Stefano, MD, PhD, Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. P…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Antonio Avallone, MD, and Alfonso De Stefano, MD, PhD, Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy; and Davide Ciardiello, MD, PhD, Division of Gas…

ORCID-Profile: Antonio Avallone, Alfonso De Stefano

Zitieren

APA

Avallone, A., De Stefano, A., & Ciardiello, D. (2026). Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study. Journal of Clinical Oncology, 44(23), 2253-2254. https://doi.org/10.1200/jco-26-00227

Vancouver

Avallone A, De Stefano A, Ciardiello D. Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study. Journal of Clinical Oncology. 2026;44(23):2253-2254. doi:10.1200/jco-26-00227

BibTeX
@article{Avallone2026,
  author = {Avallone, Antonio and De Stefano, Alfonso and Ciardiello, Davide},
  title = {Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {23},
  pages = {2253--2254},
  doi = {10.1200/jco-26-00227}
}
Kostenlos starten →